406913-93-7

Usage

Uses

Used in Chemical Reactions and Processes:
(2S)-1,4-Dioxan-2-yl-methanol is used as a solvent for its ability to dissolve a wide range of substances, facilitating various chemical reactions and processes.
Used in Pharmaceutical and Agrochemical Synthesis:
In the pharmaceutical and agrochemical industries, (2S)-1,4-Dioxan-2-yl-methanol is utilized as a key intermediate in the synthesis of different compounds, contributing to the development of new drugs and agricultural products.
Used as a Chiral Auxiliary in Asymmetric Synthesis:
(2S)-1,4-Dioxan-2-yl-methanol is employed as a chiral auxiliary in asymmetric synthesis, playing a crucial role in the production of enantiomerically pure compounds, which are essential for the efficacy and safety of many pharmaceuticals.
Used in Research and Development:
Due to its unique properties, (2S)-1,4-Dioxan-2-yl-methanol is also used in research and development for the creation of new materials and products, driving innovation across multiple scientific fields.

Upstream product

• 406913-89-1 Phthalic acid mono-(R)-1-[1,4]dioxan-2-ylmethyl ester 
• 934346-80-2 (S)-2-((2-chloroethoxy)methyl)oxirane 
• 934346-53-9 (R)-1-(2-chloroethoxy)-3-chloropropan-2-ol 
• 29908-11-0 (+/-)-2-(hydroxymethyl)-1,4-dioxane 
• 18371-74-9 1-chloro-3-(2-hydroxyethoxy)-2-propanol 
• 406913-84-6 2-hydroxymethyl-1,4-dioxane hydrogen phthalate 
• 917882-63-4 (2S)-2-[(benzyloxy)methyl]-1,4-dioxane 
• 27905-76-6 2-(2-chloroethoxy)-3-chloropropan-2-ol 
• 861852-08-6 (2R)-2-[(2-chloroethoxy)methyl]oxirane 
• 51594-55-9 (R)-(-)-epichlorohydrin 
• 107-07-3 2-chloro-ethanol 

Downstream Products

• 934346-74-4 (R)-1,4-dioxane-2-carboxaldehyde 
• 1067230-84-5 [(2R)-1,4-dioxan-2-yl]methyl 4-methylbenzenesulfonate 
• 1207624-26-7 6-Bromo-3-cyclohex-1-en-1-yl-1-[(2S)-1,4-dioxan-2-ylmethyl]-5-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 917882-57-6 benzyl [(2S)-1,4-dioxan-2-ylmethyl]methylcarbamate 
• 917882-66-7 N-((2R)-1,4-dioxan-2-ylmethyl)-N-methyl-N’-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]sulfamide 
• 1346262-49-4 (R)-2-{N-[((S)-1,4-dioxan-2-yl)methyl]-4-chlorophenylsulfonamido}-5,5,5-trifluoropentanamide 
• 1337470-52-6 (S)-(1,4-dioxan-2-yl)methanamine 
• 1569298-20-9 C₁₀H₁₉NO₄ 

Relevant academic research and scientific papers

CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS

The disclosure includes compounds of Formula (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1 Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.

1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES

The present invention relates to lH-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors for treating neoplastic, autoimmune or neurodegenerative diseases. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 162 to 233; examples 1 to 8; table; compound examples cpd-1 to cpd-135; biological examples 1 to 4).

Method for Producing Diarylpyridine Derivatives

The present invention relates to a novel method for producing diarylpyridine derivatives, and the object of the present invention is to provide a novel, industrially useful method. The present inventors developed a novel method for synthesizing pyridine r

HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR

A pro-apoptotic solid dispersion comprises, a Bcl -2 family protein inhibitory compound of Formula A as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier, and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises subjecting to elevated temperature the compound of Formula A, the water-soluble polymeric carrier, and the surfactant to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; and cooling the resulting extrudate to provide a solid matrix comprising the polymeric carrier, and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl -2 family proteins, for example cancer or an immune or autoimmune disease.

Meso-Tetra(dioxanyl)porphyrins: Neutral, low molecular weight, and chiral porphyrins with solubility in aqueous solutions

The synthesis of the low-molecular weight, meso-Tetra(dioxan-2-yl)porphyrin with considerable solubility in aqueous solution is described. The key intermediate dioxan-2-carbaldehyde is accessible in either racemic or in stereo-pure forms from commercially available starting materials in three steps. Using 4 × 1 or 2 + 2-Type syntheses provide the porphyrin in modest yields. While the racemic aldehyde created an intractable mixture of diastereomers, the enantiopure aldehyde created a single enantiomer of the target porphyrin. The porphyrin was spectroscopically characterized. As its free base or zinc complex, it showed excellent solubility properties in organic and aqueous solvents, though free water-solubility was not achieved. The work expands on the availability of chiral porphyrins and neutral porphyrins with considerable solubility in aqueous solution.

BCL-2 INHIBITORS

The disclosure includes compounds of Formula (I), (I) wherein Z, Q1, Q3, Q4, Q5, Q6, Q7, R0, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, g, k, m, n, s, v, j, L, Z1, and, W are defined herein. Also disclosed is a method for treating a neoplastic disease and autoimmune disease with these compounds.

BCL-2 INHIBITORS

The disclosure includes compounds of Formula (A), (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1, Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.

1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES

The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.

QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS

Disclosed herein are protein kinase inhibitors, more particularly novel quinazoline derivatives and pharmaceutical compositions thereof,and method of use thereof.

INHIBITORS OF BETA-SECRETASE

The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of β-amyloid aggregates.